At Citius Pharmaceuticals, Eugene Holuka has been appointed to the company’s board
Envigo’s board has appointed Adrian Hardy as president and CEO. He will also join the company’s board of directors. Brian Cass, the previous CEO, will become executive chairman.
Intensity Therapeutics, a biotechnology company developing proprietary cancer immunotherapy products, has added Declan Doogan and Emer Leahy to its board.
BioOutsource, a subsidiary of Sartorius Stedim Biotech, an international supplier for the biopharmaceutical industry, has appointed Ravin Mehta as technical sales specialist.
Takeda, Japan’s largest drug maker, has made changes to the top management at its Indian operations. Ashok Bhattacharya, the current head of commercial operations, has replaced Aman Bajaaj as general manager.
The board of speciality chemicals distributor Azelis has appointed Thijs Bakker as CFO, following the retirement of Martin Hollenhorst. Also Laurent Nataf has been promoted from COO to CEO and president, Asia Pacific; Anna Bertona has moved from chief strategy and principal officer to COO, EMEA; and Michael Roney has joined its board.
Contract development and manufacturing organisation, Recipharm has appointed Ann Flodin as general manager of its wholly owned US subsidiary, Recipharm Laboratories.
Jonathan Garen has been appointed as chief business officer for uniQure, responsible for strategic transactions, focusing on business development and alliance management.
Merus Labs International has announced two additions to its executive leadership team: Michael Bumby becomes CFO, succeeding Andrew Patient, and Frank Fokkinga has been appointed VP, global regulatory affairs, quality and compliance.
Brian Lake has joined CXR Biosciences as an associate toxicologist.
PureTech Health, a cross-disciplinary biotech company developing novel medicines, has appointed Feng Zhang to its scientific advisory board. The company has also appointed Jeff Stevens, as VP, growth strategy & operations.
Biopharmaceutical company, Second Genome has appointed Glenn Nedwin as CEO, president and member of the company’s board.
Cornelius Group, a European distributor of raw materials and ingredients, has made two new appointments: Kerry Dodd has joined the company as business manager, health and nutrition; and Rachael Atwell has been recruited as business development manager, care UK division.
Promethera Biosciences, a Belgian biopharmaceutical company, has established a scientific and medical advisory board: Massimo Pinzani (UCL, UK); Anil Dhawan (King’s College Hospital, London, UK); Sanjeev Gupta (Albert Einstein College of Medicine, New York, US); Michael Ott (Hannover Medical School, Germany); Andreas Nuessler (Eberhard Karls University, Tuebingen, Germany); and Patrice Cani (Université Catholique de Louvain, Brussels, Belgium).
Drug company Sun Pharma has named Abhay Gandhi as CEO of its North American business.
Cancer Research UK has appointed Peter Chambré as a trustee. Chambré also chairs Cancer Research Technology, the charity’s commercialisation arm.
LEUKOCARE has announced the election of Andreas Rummelt as a new member of its supervisory board.
At e-Therapeutics, Iain Ross has been appointed executive chairman. In addition, Steve Medlicott, CFO has been appointed interim COO.
Peakdale Molecular has added two new members to its team. Christopher Doe joins as head of biology and Sascha Hartmann has joined the business development team as business development manager – biology services.
Biotechnology company, Quartet Medicine has announced that its board has appointed Gerhard Koenig as CEO.
Trevor Jones, former head of r&d at Wellcome, has been appointed as an advisor to the board of Concept Life Sciences, advising on current and prospective areas of business.
At Bristol-Myers Squibb, Fouad Namouni has been appointed oncology development head.
Suzanne Rowland has joined Ashland as group VP, industrial specialties, with overall responsibility for the coatings, adhesives and other industrial end markets.
The US Food and Drug Administration (FDA) has named Richard Pazdur as the acting director of the newly established FDA Oncology Center of Excellence
Biotech company, Chronos Therapeutics has appointed Fraser Murray and Timothy Schulz-Utermoehl, as VPs of pre-clinical development
Halocarbon Products Corporation, a producer of specialty fluorochemicals, inert lubricants and inhalation anaesthetics, has announced that Carl Walther has joined as manager, technical services/support
SYGNIS has named Heikki Lanckriet as co-CEO. He has also been appointed to the newly created position of CSO, and will become a member of the management board, along with Pilar de la Huerta, who will partner him as co-CEO and also as CFO
Torax Medical has named Chas McKhann as chief commercial officer.